Hyperglucagonemia and Its Suppression: Importance in the Metabolic Control of Diabetes

New England Journal of Medicine

Volumn 299, Issue 9, 1978, Pages 433-436

  Raskin, Philip ^a   Unger, Roger H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; INSULIN; SOMATOSTATIN;

DIABETES MELLITUS; DIET; DRUG THERAPY; ENDOCRINE SYSTEM; GLUCOSE BLOOD LEVEL; HYPERGLUCAGONEMIA; INTRAVENOUS DRUG ADMINISTRATION; JUVENILE DIABETES MELLITUS; MAJOR CLINICAL STUDY; RADIOIMMUNOASSAY; THERAPY;

EID: 0018122474     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197808312990901     Document Type: Article

References (21)

1. Presented at the 38th annual meeting of the American Diabetes Association, Boston, Massachusetts, June 13, 1978.
2. Unger RH, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14–16, 1975
3. Dobbs R, Sakurai H, Sasaki H, et al: Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187: 544–547, 1975
4. Gerich JE, Lorenzi M, Bier DM, et al: Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med 292: 985–989, 1975
5. Unger RH: The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes 25: 136–151, 1976
6. Sherwin RS, Fisher M, Hendler R, et al: Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 294: 445–461, 1976
7. Cherrington AD, Vranic M: Effect of interaction between insulin and glucagon on glucose turnover and FFA concentration in normal and depancreatized dogs. Metabolism 23: 729–744, 1974
8. Bomboy JD, Lewis SB, Lacy WW, et al: Transient stimulatory effect of sustained hyperglucagonemia on splanchnic glucose production in normal and diabetic man. Diabetes 26: 177–184, 1977
9. Felig P, Wahren J, Hendler R: Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest 58: 761–765, 1976
10. Gerich JE, Schultz TA, Lewis SB, et al: Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. Diabetologia 13: 537–544, 1977
11. Wahren J, Felig P: Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet 2: 1213–1216, 1976
12. Raskin P, Unger RH: Effects of exogenous hyperglucagonemia in insulin-treated diabetics. Diabetes 26: 1034–1039, 1977
13. Cherrington AD, Lacy WW, Chiasson JL: Effect of glucagon on glucose production during insulin deficiency in the dog. J Clin Invest (in press)
14. Faloona GR, Unger RH: Glucagon, Methods of Hormone Radioimmunoassay. Edited by BM Jaffe, HR Behrman. New York, Academic Press, 1974, pp 317–330
15. Santeusanio F, Faloona GR, Unger RH: Suppressive effect of secretin upon pancreatic alpha cell function. J Clin Invest 51: 1743–1749, 1972
16. March WH, Fingerhut B, Miller H: Automated and manual direct methods for the determination of blood urea. Clin Chem 2: 824–827, 1965
17. McGarry JD, Foster DW: The regulation of ketogenesis from oleic acid and the influence of antiketogenic agents. J Biol Chem 246: 6247–6253, 1971
18. Sacks H, Waligora K, Matthews J, et al: Inhibition by somatostatin of glucagon-induced glucose release from the isolated perfused rat liver. Diabetes 26: 358, 1977
19. Holst JJ: Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity. Diabetologia 13: 159–169, 1977
20. Raskin P, Unger RH: Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes 27: 411, 1978
21. Rizza R, Gerich JE: The effect of intermittent endogenous hyperglucagonemia on glucose metabolism in normal and diabetic man. Diabetes 27: Suppl 1: 455, 1978